Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Neuroendocrine Prostate Cancer Cells with character “switching” capabilities!

Cancer therapy by targeting TGFβ signaling

AXL receptor: a new companion of the ACE2 receptor which helps SARS-CoV-2 to enter the human body

Neuroendocrine Prostate Cancer Cells with character “switching” capabilities!
  • BiotechToday
  • World

Neuroendocrine Prostate Cancer Cells with character “switching” capabilities!

bioxone January 16, 2021January 16, 2021

Richismita Hazra, Amity University Kolkata

Cells often manifest reversible changes in their properties and phenotypes which is known as cellular plasticity. This is also termed lineage plasticity or lineage switching. Cancer cells use this phenomenon to adapt to stressful conditions and this leads to cancer progression. Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that is associated with enhanced plasticity. This may arise newly or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. Presently there are no effective treatments for NEPC and this is a major problem faced by men. 

Recently researchers from Flinders Institute of South Australia reported their findings on a novel mechanism in which prostate cancer cells are capable of ‘switch’ or alter their character due to which they become resistant to therapy. According to this study, the microRNA “miR-194” is responsible for the enhancement of plasticity in prostate cancer due to which the emergence of NEPC occurs. It was observed that target to miR-194 caused hindrance to the proliferation of cancer models with neuroendocrine characteristics. This molecule was found to be negatively associated with androgen receptor signaling.

Although this field demands further studies before the clinical approach, this study highlights the process of evolution of prostate cancers in therapeutic responses. 

Also read:Cancer therapy by targeting TGFβ signaling

Source: https://doi.org/10.1016/j.celrep.2020.108585

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Aggressive variant cancer Cancer Therapy cancer treatment Carcinoma cell Cellular plasticity hormones Men Neuroendocrine phenotypes prostate prostate cancer Receptor signalling Signalling stress Therapeutic resistance treatment

2 thoughts on “Neuroendocrine Prostate Cancer Cells with character “switching” capabilities!”

  1. Dr. Mukesh Kumar Meena says:
    January 16, 2021 at 6:25 am

    This time every type of cancer is so spreading and dangerous.

    Reply
  2. Pingback: AXL receptor: a new companion of the ACE2 receptor which helps SARS-CoV-2 to enter the human body - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

AXL receptor: a new companion of the ACE2 receptor which helps SARS-CoV-2 to enter the human body

bioxone January 16, 2021

Parnad Basu, Amity University Kolkata The pandemic caused by COVID-19 is continuing still. The causative viral pathogen of COVID-19 is SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This SARS-CoV-2 actually belongs to the β coronavirus genus along with SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (middle east respiratory syndrome coronavirus). Although SARS-CoV-2 targets the […]

AXL receptor

Related Post

  • BiotechToday
  • World

AI Literacy in Early Childhood Education: Challenges and Opportunities

DNA tales September 25, 2023September 25, 2023

Nikita Shaileshbhai Patel, Assistant Professor, Department of Pharmaceutical Quality Assurance and Chemistry, Arihant School of Pharmacy and Bio-Research Institute, Gujarat, India. AI revolutionising digital literacy Currently, Artificial Intelligence (AI) literacy is a developing area of study in digital literacy education. AI literacy has certain potential as well as difficulties. There were a few difficulties, such […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Gene therapy clinical trials for rare Angelman syndrome put on hold

bioxone November 7, 2020November 6, 2020

Surupa Chakraborty, Amity University Kolkata A new gene therapy clinical trial for treating Angelman syndrome has been put to hold after two candidates temporarily lost their ability to walk. GTX102, the drug used in the clinical trial was developed by a California-based biopharmaceutical company Ultragenyx, in collaboration with GeneTx, a Florida-based biotech startup. The trial […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • World

Is Embryonic Evolution’s pace associated with differences in protein stability?

bioxone September 19, 2020September 19, 2020

-Ayooshi Mitra, Amity University, Kolkata While many developmental processes have evolutionarily preserved the molecular and cellular mechanisms, the pace at which they operate varies considerably between species. The pace of embryonic development determines the rate of individual processes of differentiation and the overall development duration. Comparing conserved and well-characterized processes of development in different species […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy